Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07387367 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
A Phase 3 study of Adenovirus Infections, sponsored by SymBio Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT07387367: Recruiting Phase 3 study of Adenovirus Infections, sponsored by SymBio Pharmaceuticals.
NCT07387367 is a Phase 3 study of Adenovirus Infections that is actively recruiting participants, run by SymBio Pharmaceuticals. The registered enrollment target is 180 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07387367, a Phase 3 study of Adenovirus Infections, is actively recruiting participants, sponsored by SymBio Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized, open-label, parallel group, two-arm, multi-center assessment will compare IV BCV with IV CDV in adult and pediatric allogeneic HCT recipients with AdV viremia. A virologic response-driven approach to duration of treatment will be evaluated, in which randomized subjects are treated with either BCV or CDV until AdV viremia is confirmed as undetectable or until a maximum of 12 weeks of therapy, whichever occurs first. All subjects will be followed for a total of 24 weeks post-randomization, regardless of treatment assignment. Subjects will be assessed on a weekly basis through the end of treatment visit (EOT). Additional assessments will be performed at the test of cure (TOC) visit, which is 4 weeks after the last dose of study drug and at Weeks 12 and 24 post W1D1.
Primary Outcome
The primary efficacy endpoint is defined as AdV virological success at W5D1. -Proportion of subjects with AdV virological success
Conditions Studied
Interventions
- DRUG cidofovir
- DRUG Brincidofovir
Study Locations (20)
California
- City of Hope - Duarte
- University of California Davis - Sacramento
- Rady Children's Hospital - San Diego
Illinois
- Ann and Robert H Lure Children's Hospital - Chicago
- University of Chicago - Chicago
Massachusetts
- Dana-Farber Cancer Institute-Brighman and Women's - Boston
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center - Boston
New York
- Cohen Children's Medical Center - New Hyde Park
- Weill Cornell Medicine - New York
Arizona
- Phoenix Children's Hospital - Phoenix
Colorado
- Children's Hospital Colorado-Center for Cancer and Blood Disorders - Aurora
District of Columbia
- Children's National Hospital - Washington D.C.
Georgia
- Children's Healthcare of Atlanta/Emory - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-02-15 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 3 |
What NCT07387367 shows while recruiting
NCT07387367 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Adenovirus Infections appearing as the primary indexed condition, and to 2 interventions - of which cidofovir is the first listed.
NCT07387367 names 20 study sites across 15 states, led by California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07387367 about?
NCT07387367 is a clinical study titled "A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT". This randomized, open-label, parallel group, two-arm, multi-center assessment will compare IV BCV with IV CDV in adult and pediatric allogeneic HCT recipients with AdV viremia. A virologic response-driven approach to duration of treatment will be evaluated, in which randomized subjects are treated w...
What is the current status of trial NCT07387367?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2026-02-15. Estimated completion is 2028-06-30.
What conditions does trial NCT07387367 study?
This clinical trial studies the following conditions: Adenovirus Infections.
What interventions are being tested in trial NCT07387367?
The interventions under investigation include: cidofovir (DRUG), Brincidofovir (DRUG).
Who is sponsoring clinical trial NCT07387367?
This trial is sponsored by SymBio Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07387367 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07387367's enrollment target sits among peer trials
180 1423rd of 2000 higher than 564 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI